AI drug‑discovery startup Iambic closed a $100 million financing to fund clinical development of oncology candidates discovered by its generative chemistry platform. The round follows presentations of clinical or preclinical data for a breast cancer asset at the European Society for Medical Oncology (ESMO) meeting. The financing will support IND‑enabling studies and early clinical trials, signaling continued investor interest in AI‑driven drug discovery where platforms aim to compress hit‑to‑lead timelines. Iambic’s raise joins a broader funding wave backing computationally discovered therapeutics. Investors will watch whether Iambic’s clinic‑stage data validate its algorithmic selection process and translate to differentiated efficacy or safety profiles in humans.